Legend surges on early data for ‘in vivo’ lymphoma cell therapy
BioPharma Dive
Initial findings show that the therapy reduced or eliminated disease signs in all recipients, sparking hopes that the treatment might be competitive with ex vivo medicines like Novartis Kymriah.
pharminent
June 3, 2026 (Last updated: June 4, 2026)
BioPharma Dive
Initial findings show that the therapy reduced or eliminated disease signs in all recipients, sparking hopes that the treatment might be competitive with ex vivo medicines like Novartis Kymriah.